SAB Biotherapeutics Inc SABS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB BIO to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $2.94
- Day Range
- $2.93–2.97
- 52-Week Range
- $2.44–5.09
- Bid/Ask
- $2.91 / $3.07
- Shares Outstanding
- 90.09M
- Market Cap
- $271.14M
- Volume/Avg
- 27,071 / 534,724
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 86
- Website
- https://www.sab.bio
Valuation
Metric | SABS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SABS
Financial Strength
Metric | SABS |
|---|---|
Quick Ratio | 7.13 |
Current Ratio | 7.28 |
Interest Coverage | — |
Quick Ratio
SABS
Profitability
Metric | SABS |
|---|---|
Return on Assets (Normalized) | −25.04% |
Return on Equity (Normalized) | −27.85% |
Return on Invested Capital (Normalized) | −29.51% |
Return on Assets
SABS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|jZn<Q# | LOCK|Pv!Y | $138B | |||
| Moderna Inc MRNA | LOCK|<^j?r?t | LOCK|$GX | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%@!sBM# | LOCK|G^cW | $93B | |||
| argenx SE ADR ARGX | LOCK|^Y>&L>> | LOCK|sXt | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Wl<Q!t | LOCK|!l | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|gqCb?DS | LOCK|CbjG | $30B | |||
| Incyte Corp INCY | LOCK|K>sV<s? | LOCK|J? | $24B | |||
| BioNTech SE ADR BNTX | LOCK|QkKB$%M | LOCK|lf> | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<VsmXL | LOCK|l#^% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|@B?P&W | LOCK|s! | $15B |
United States